Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Beijing, etc., China Clinical Trials

A listing of Beijing, etc., China clinical trials actively recruiting patients volunteers.

RESULTS

Found (18) clinical trials

The Evaluation of Pelvic Floor Muscle Function: A Reliability and Correlation Study

This is a study using a randomized crossover blind method.All the volunteers are divided into 2 groups randomly. At the first time, a gynecological physician evaluates patient's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling patient her result, and ...

Phase N/A

1.31 miles

Learn More »

Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI

Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor. Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist ...

Phase

1.78 miles

Learn More »

KN035 for dMMR/MSI-H Advanced Solid Tumors

Later-line therapies after failure of standard treatments for advanced colorectal and non-colorectal cancer patients are limited. Mismatch repair (MMR) deficiency or microsatellite instability-high (MSI-H) played a role of positive predictive factor, which had been documented after the pembrolizumab and nivolumab trial were reported, for PD-1 blockade monotherapy in patients with ...

Phase

1.93 miles

Learn More »

Recombinant SeV-hFGF2/dF Injection for PAOD

Lower extremity arteriosclerosis obliterans is due to the formation of atherosclerotic plaque in the lower extremities, resulting in the stenosis and occlusion of the artery, leading to chronic ischemia of the limbs. Although bypass surgery and angioplasty ( or interventional therapy ) are effective methods for vascular treatment in patients ...

Phase

2.57 miles

Learn More »

Prediction of Preeclampsia by Comprehensive Markers.

The prospective multi-center observational study aimed to recruit at least 12,000 pregnant woman during the first trimester conducted among 21 medical centers in China. The medical history of each candidate was recorded , blood pressure was measured , blood sample was taken between 11 gestational weeks and 13+6 gestational weeks, ...

Phase N/A

2.77 miles

Learn More »

Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke

NBO is a nonpharmacological measure of neuroprotection. The purpose of our study is to evaluate the safety and efficiency of NBONormobaric hyperoxia) in the acute ischemic stroke patients who received endovascular treatment. Looking for more clinical evidence for the ischemic stroke patients who will be treated with NBO in the ...

Phase N/A

2.77 miles

Learn More »

Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

In the phase Ib portion, an escalated dose cohort is recruited to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of anlotinib when given in combination with gemcitabine/cisplatin. The phase II portion is designed to characterize the efficacy and safety of the combination therapy in previous ...

Phase

2.85 miles

Learn More »

NPPV vs IPPV in Severe Chronic Obstructive Pulmonary Disease Exacerbation

In part of the patients who were AECOPD with pH <7.25 , preliminary studies have shown that NPPV can avoid tracheal intubation in 40% to 60% patients, and also reduce the incidence of VAP. Recently, large-scale comparative effectiveness research (CER) also found that compared with invasive ventilation, NPPV can reduce ...

Phase N/A

3.04 miles

Learn More »

High Flow Nasal Cannula vs NPPV in Moderate Chronic Obstructive Pulmonary Disease Exacerbation

Recently, many clinical studies have showed that HFNC can be successfully used in patients with hypoxemic respiratory failure to improve the comfort, to attenuate respiratory failure and to decrease the rate of tracheal intubation and mortality. Although theoretically HFNC is a potential and ideal treatment for AECOPD patients, the related ...

Phase N/A

3.04 miles

Learn More »

TAB014 in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

The screening period was 28 days. The classification of CNV will be determined by Fundus Fluorescein Angiography ( FFA ) at the study centers. Subjects will receive intravitreal injections of TAB014 Monoclonal Antibody Injection in one eye ( the study eye ). Subjects will only receive single intravitreal dose.

Phase

4.44 miles

Learn More »